Grundinformationen
- CAS
1841-19-6- Standard-SMILES
O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2- InChIKey
QOYHHIBFXOOADH-UHFFFAOYSA-N- Summenformel
- C29H31F2N3O
- Durchschnittliche Molmasse
- 475,6 g/mol
- Monoisotopische Masse
- 475,24351894
Überblick
8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one is a diarylmethane.
Namen und Bezeichner
- Bevorzugter Name
- Fluspirilene
- IUPAC
- 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
- Lokaler Name
- Fluspirilen
- Englischer Name
- FLUSPIRILENE
- Summenformel
- C29H31F2N3O
- Molmasse
- 475.57
Namen und Synonyme
Fluspirilene1841-19-6RedeptinImapFluspirilenoMcN-JR-62188-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-oneR 6218FluspirilenumDTXSID7045152R-6218C5QA4GLR9M
Weitere Namen anzeigen
FluspirilenFluspirilene CRSFluspirilene (R 6218FLUSPIRILENE USP/EP/BPParoxetine EP IMpurity C
8-(4,4-Bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro-(4.5)decan-4-one1,3,8-Triazaspiro(4.5)decan-4-one, 8-(4,4-bis(4-fluorophenyl)butyl)-1-phenyl-SpirodiflamineDTXCID50251521,3,8-Triazaspiro[4.5]decan-4-one, 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-Beta, Fluspirilen8-(4,4-bis(4-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one8-(4,4-bis(4-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro(4.5)decan-4-one
Datenbank-Bezeichner
- CAS
1841-19-6- PubChem CID
- 3396
- DTXSID
DTXSID7045152- ChEMBL
CHEMBL46516
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 5,6
- Polarare Oberfläche (TPSA)
- 35,6 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 5
- Frei drehbare Bindungen
- 7
- Schwere Atome
- 35
- Formalladung
- 0
- Komplexität
- 653
Experimentelle und physikochemische Eigenschaften
Drugs
Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals -> Nervous system -> Antipsychotics
LogP
5.86
5.86
Solubility1.67e-03 g/L
Melting Point187.5-190
Physical DescriptionSolid
Dissociation Constants
8.66
7.7
Physikochemische Eigenschaften
- Schmelzpunkt
- 187.5 · 187.5-190°
- Siedepunkt
- 668.9 · 668.9±55.0 °C(Predicted)
- Dichte
- 1.1634 · 1.1634 (estimate)
- storage temp.
- room temp
- Löslichkeit
- DMSO: soluble
- Aggregatzustand
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Danger
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
P264, P270, P273, P301+P316, P321, P330, P391, P405, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Gefahrenhinweise
Other Safety InformationIMAP assessments - 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (100%)
Toxikologische Informationen
Drug Induced Liver Injury
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
fluspirilene
DILI Positive
Intramuscular
DOI:10.1016/j.drudis.2019.09.022
Sicherheitsdaten
- wgk
- 3
- ridadr
- 3249
- RTECS-Nr.
- XX8750000
- Toxizität
- LD50 i.m. in rats: 146 ±14 mg/kg (Janssen)
- hazard_class
- 6.1(b)
- packing_group
- III
- Speicherklasse
- 11 - Combustible Solids
Chemie und Industrie
Pharmakologische Informationen
ATC Code
N05AG01
N - Nervous system
QN - Nervous system
Pharmacodynamics
Fluspirilene is a relatively long-acting injectable depot antipsychotic drug used for schizophrenia. Fluspirilene does not differ greatly from other depot antipsychotics (fluphenazine decanoate, fluphenazine enathate, perphenazine onanthat, pipotiazine undecylenate) with respect to treatment efficacy, response or tolerability. Outcomes suggest that fluspirilene does not differ significantly from oral antipsychotics or in different weekly regimens, although much cannot be inferred because of the shortage of trials.
MeSH Pharmacological Classification
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
Cellular LocationsMembrane
Anwendungen
BeschreibungFluspirilene is a potent, non-competitive antagonist of agonist-activated L-type calcium channels (IC50 = 0.03 μM). In addition to its use in research as a calcium channel blocker, fluspirilene has potential application as an antipsychotic in schizophrenia.
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…